Quarterly report · Q2
3604.TEDINET S100SAC7
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥14.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥30.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥15.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥100m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥279m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥218m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥825m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥341m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥289m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥338m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥179m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥747m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥217m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥208m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥222m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥19.5bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥19.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥17.0bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥12.0bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥12.2bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.5bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.2bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.3bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.6bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥866m | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥339m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥175m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥62m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥205m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥705m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥122m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥4m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥858m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥223m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥30.84 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.47 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥128.96 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.46 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.32 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 34.9% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment ordinary income | 2023-04-01 → 2023-09-30 | −¥294m |
| jpcrp040300-q2r_E00614-000Consumerreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥10.5bn |
| jpcrp040300-q2r_E00614-000Consumerreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥10.5bn |
| jpcrp040300-q2r_E00614-000Consumerreportable segment | segment ordinary income | 2023-04-01 → 2023-09-30 | ¥389m |
| jpcrp040300-q2r_E00614-000Medicalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E00614-000Medicalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E00614-000Medicalreportable segment | segment ordinary income | 2023-04-01 → 2023-09-30 | ¥123m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥14.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥14.6bn |
| Total Of Reportable Segments And Otherssegment total | segment ordinary income | 2023-04-01 → 2023-09-30 | ¥512m |
| Reconciling Itemsreconciling | segment ordinary income | 2022-04-01 → 2022-09-30 | −¥244m |
| jpcrp040300-q2r_E00614-000Consumerreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥10.9bn |
| jpcrp040300-q2r_E00614-000Consumerreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥10.9bn |
| jpcrp040300-q2r_E00614-000Consumerreportable segment | segment ordinary income | 2022-04-01 → 2022-09-30 | ¥449m |
| jpcrp040300-q2r_E00614-000Medicalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E00614-000Medicalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E00614-000Medicalreportable segment | segment ordinary income | 2022-04-01 → 2022-09-30 | ¥136m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥15.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥15.1bn |
| Total Of Reportable Segments And Otherssegment total | segment ordinary income | 2022-04-01 → 2022-09-30 | ¥585m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 510
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |